Updated data from a Phase 1/1b clinical trial evaluating TG Therapeutics' (TGTX +2.2%) ublituximab, a glycoengineered anti-CD20 monoclonal antibody, combined with PI3K delta inhibitor umbralisib (TGR-1202) (called "U2") and chemo agent bendamustine, in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) showed a treatment effect. The results were presented at ASH in San Diego.
38 patients were evaluable for efficacy. The overall response rate (ORR) in DLBCL patients was 48% (n=12/25), including nine complete responders. The ORR in FL patients was 85% (n=11/13), including seven complete responders.
Previously: TG Therapeutics up 7% on positive umbralisib + ublituximab data (Nov. 1)
Subscribe for full text news in your inbox